As AML bulk cells are heterogeneous ... We have demonstrated for the first time that MRD assessment by flow cytometry at aplasia is feasible and has an independent prognostic value next to ...

Flow Cytometry Indicates Treatment Response in AML For children with acute myeloid leukemia (AML), minimal residual disease (MRD) activity, as measured using flow cytometry, is a good indicator of ...

Measurable residual disease (MRD) can predict disease progression in patients who have acute myeloid leukemia (AML), acute ... multiparameter flow-cytometry (MFC), quantitative polymerase chain ...

"These results will help establish flow cytometry testing for minimal residual disease as a routine tool for guiding therapy of acute myeloid leukemia and identifying patients early who are at ...

“MRD assessment by flow cytometry to define response to treatment can be applied to most AML patients and is clearly prognostic, differentiating patients with a higher risk of relapse ...

A new single-tube flow panel for the development of AML therapies ... and evaluating measurable residual disease (MRD) in AML samples. The new panel unleashes the power of Cytek’s Full Spectrum ...

Patients with acute myeloid leukemia (AML) often reach complete remission, but relapse rates remain high. Next-generation sequencing enables the detection of molecular minimal residual disease in ...

NewsVoir New Delhi [India], June 16: To achieve a consensus on a suitable panel and analysis strategy to report Acute Myeloid Leukemia - Measurable Residual Disease (AML-MRD) by flow cytometry, BD ...

Relapsed AML is a dangerous and deadly thing. And obviously what we would love to do is never have a patient relapse. There's a lot of discussion of MRD, or measurable residual disease ...